Nomifensine maleate
(Merital, Hoechst-Roussel)

by
Fields ED
Department of Pharmacology,
Georgetown University
School of Medicine,
Washington, DC 20007-2195, USA.
Drug Intell Clin Pharm 1982 Jul-Aug; 16(7-8):547-52


ABSTRACT

Nomifensine is an isoquinoline antidepressant that inhibits the reuptake of dopamine at central synapses. It also inhibits norepinephrine reuptake but is only a weak inhibitor of 5-hydroxytryptamine. Open and controlled trials comparing nomifensine with placebo and other standard antidepressants have shown it to be an effective antidepressant in divided doses up to 200 mg/d. The full dosage range of 50-200 mg/d is well tolerated, and doses can be selected to suit patient disease, age, and therapeutic response. Minimal anticholinergic and sedative side effects and no impairment of psychomotor performance make nomifensine a suitable drug for use in a wide variety of ambulatory outpatients, including the elderly. A relative lack of cardiotoxicity and epileptogenic activity add to this profile; the safety of the drug, when taken in overdose, has been documented. However, the place of nomifensine in the treatment of depression, relative to other antidepressants, is still unclear.
Dopamine
Bupropion
Amineptine
Noradrenaline
Nomifensine: overview
Nomifensine: pharmacology
Noradrenaline and dopamine
Nomifensine: pharmacokinetics
Nomifensine and hemolytic anaemia
Nomifensine, noradrenaline and dopamine



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family